CL2011001232A1 - Pharmaceutical combination comprising an antibody that specifically recognizes cd38 and at least cytarabine; and its use for cancer treatment - Google Patents

Pharmaceutical combination comprising an antibody that specifically recognizes cd38 and at least cytarabine; and its use for cancer treatment

Info

Publication number
CL2011001232A1
CL2011001232A1 CL2011001232A CL2011001232A CL2011001232A1 CL 2011001232 A1 CL2011001232 A1 CL 2011001232A1 CL 2011001232 A CL2011001232 A CL 2011001232A CL 2011001232 A CL2011001232 A CL 2011001232A CL 2011001232 A1 CL2011001232 A1 CL 2011001232A1
Authority
CL
Chile
Prior art keywords
cytarabine
antibody
cancer treatment
pharmaceutical combination
specifically recognizes
Prior art date
Application number
CL2011001232A
Other languages
Spanish (es)
Inventor
Pascale Vrignaud Patricia Lejeune
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40627502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001232(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2011001232A1 publication Critical patent/CL2011001232A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

Combinación farmacéutica que comprende un anticuerpo que reconoce específicamente la cd38 y al menos citarabina; y su uso para el tratamiento de cáncerPharmaceutical combination comprising an antibody that specifically recognizes cd38 and at least cytarabine; and its use for cancer treatment

CL2011001232A 2008-11-28 2011-05-26 Pharmaceutical combination comprising an antibody that specifically recognizes cd38 and at least cytarabine; and its use for cancer treatment CL2011001232A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08291118A EP2191842A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine

Publications (1)

Publication Number Publication Date
CL2011001232A1 true CL2011001232A1 (en) 2012-02-10

Family

ID=40627502

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001232A CL2011001232A1 (en) 2008-11-28 2011-05-26 Pharmaceutical combination comprising an antibody that specifically recognizes cd38 and at least cytarabine; and its use for cancer treatment

Country Status (38)

Country Link
US (1) US20120093806A1 (en)
EP (2) EP2191842A1 (en)
JP (2) JP2012510463A (en)
KR (1) KR101715958B1 (en)
CN (2) CN107096022A (en)
AR (1) AR073425A1 (en)
AU (1) AU2009321251B2 (en)
BR (1) BRPI0921858B1 (en)
CA (1) CA2745005C (en)
CL (1) CL2011001232A1 (en)
CO (1) CO6440556A2 (en)
CR (1) CR20110282A (en)
DK (1) DK2370096T5 (en)
EA (1) EA027070B1 (en)
EC (1) ECSP11011071A (en)
ES (1) ES2638926T3 (en)
HN (1) HN2011001423A (en)
HR (1) HRP20171301T1 (en)
HU (1) HUE035910T2 (en)
IL (2) IL213118A (en)
LT (1) LT2370096T (en)
MA (1) MA32899B1 (en)
MX (1) MX344973B (en)
NI (1) NI201100107A (en)
NZ (1) NZ593085A (en)
PA (1) PA8849901A1 (en)
PE (1) PE20120205A1 (en)
PL (1) PL2370096T3 (en)
PT (1) PT2370096T (en)
RS (1) RS56248B1 (en)
SG (1) SG171821A1 (en)
SI (1) SI2370096T1 (en)
TN (1) TN2011000242A1 (en)
TW (1) TWI436770B (en)
UA (1) UA104160C2 (en)
UY (1) UY32266A (en)
WO (1) WO2010061359A1 (en)
ZA (1) ZA201104064B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
RU2595839C2 (en) 2010-09-27 2016-08-27 МорфоСис АГ Anti-cd38 antibody and lenaltdomid or bortezomib for treating multiple myeloma and nhl
UA112170C2 (en) 2010-12-10 2016-08-10 Санофі ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
HUE036518T2 (en) 2012-09-25 2018-07-30 Morphosys Ag Combinations and uses thereof
EP2968555B1 (en) * 2013-03-13 2020-06-17 Sanofi Compositions comprising anti-cd38 antibodies and carfilzomib
SG11201603088RA (en) 2013-10-31 2016-05-30 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
PE20170676A1 (en) 2014-09-09 2017-05-22 Janssen Biotech Inc COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES
WO2016089960A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
KR102602754B1 (en) 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 Anti-CD38 antibodies for treating light chain amyloidosis and other CD38-positive hematological malignancies
MY192978A (en) 2015-06-22 2022-09-20 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
WO2017048872A1 (en) * 2015-09-14 2017-03-23 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating rhoh
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
SG11201803678SA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
JP2021502961A (en) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド How to treat high-risk multiple myeloma
EP3938394A1 (en) 2019-03-15 2022-01-19 MorphoSys AG Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CN112876563B (en) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 Pharmaceutical composition, preparation method and application thereof
CA3160502A1 (en) 2019-12-05 2021-06-10 Thomas Ballet Formulations of anti-cd38 antibodies for subcutaneous administration
JP2024503432A (en) 2021-01-14 2024-01-25 モルフォシス・アーゲー Use of anti-CD38 antibodies and anti-CD38 antibodies
TW202302642A (en) 2021-03-01 2023-01-16 德商莫菲西斯公司 Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
CN113278075B (en) * 2021-06-18 2021-12-14 芜湖森爱驰生物科技有限公司 Inflammation detection kit
TW202321303A (en) 2021-07-19 2023-06-01 德商莫菲西斯公司 Treatment of anti-pla2r-autoantibody-mediated membranous nephropathy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR100942002B1 (en) 1996-12-03 2010-02-12 암젠 프레몬트 인코포레이티드 Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP2003524587A (en) * 1998-06-05 2003-08-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Use of a genetically engineered antibody against CD38 to treat multiple myeloma
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
IL296666A (en) * 2005-03-23 2022-11-01 Genmab As Antibodies against cd38 for treatment of multiple myeloma
WO2008037257A2 (en) * 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CA2712989C (en) * 2008-01-23 2015-10-27 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine

Also Published As

Publication number Publication date
JP2012510463A (en) 2012-05-10
CA2745005C (en) 2020-08-11
IL213115A (en) 2017-08-31
IL213118A (en) 2017-08-31
MA32899B1 (en) 2011-12-01
CN102264386A (en) 2011-11-30
ZA201104064B (en) 2012-09-26
SI2370096T1 (en) 2017-10-30
AU2009321251A1 (en) 2010-06-03
EA027070B1 (en) 2017-06-30
TW201023863A (en) 2010-07-01
HUE035910T2 (en) 2018-05-28
BRPI0921858A2 (en) 2018-10-09
US20120093806A1 (en) 2012-04-19
MX2011005666A (en) 2011-09-30
PT2370096T (en) 2017-09-08
WO2010061359A1 (en) 2010-06-03
EP2370096B1 (en) 2017-05-31
EA201100868A1 (en) 2011-10-31
PA8849901A1 (en) 2010-07-27
SG171821A1 (en) 2011-07-28
NZ593085A (en) 2012-12-21
UY32266A (en) 2010-06-30
ECSP11011071A (en) 2011-07-29
EP2191842A1 (en) 2010-06-02
MX344973B (en) 2017-01-12
CR20110282A (en) 2011-09-20
LT2370096T (en) 2017-09-25
AU2009321251B2 (en) 2016-06-09
JP2015205893A (en) 2015-11-19
TN2011000242A1 (en) 2012-12-17
CO6440556A2 (en) 2012-05-15
HN2011001423A (en) 2014-01-13
TWI436770B (en) 2014-05-11
PE20120205A1 (en) 2012-03-03
IL213115A0 (en) 2011-07-31
UA104160C2 (en) 2014-01-10
JP6072854B2 (en) 2017-02-01
DK2370096T5 (en) 2017-09-18
PL2370096T3 (en) 2017-10-31
KR101715958B1 (en) 2017-03-14
EP2370096A1 (en) 2011-10-05
AR073425A1 (en) 2010-11-03
DK2370096T3 (en) 2017-07-17
RS56248B1 (en) 2017-11-30
BRPI0921858B1 (en) 2022-11-16
NI201100107A (en) 2011-09-26
CA2745005A1 (en) 2010-06-03
IL213118A0 (en) 2011-07-31
ES2638926T3 (en) 2017-10-24
KR20110096551A (en) 2011-08-30
CN107096022A (en) 2017-08-29
HRP20171301T1 (en) 2017-10-20

Similar Documents

Publication Publication Date Title
CL2011001232A1 (en) Pharmaceutical combination comprising an antibody that specifically recognizes cd38 and at least cytarabine; and its use for cancer treatment
CL2011001255A1 (en) Pharmaceutical combinations comprising an antibody that specifically recognizes cd38 and at least vincristine; and use of the antibody that specifically recognizes cd38 for the treatment of cancer.
CL2008002319A1 (en) Compounds derived from pyrrolopyrimidine; pharmaceutical composition comprising said compounds; and its use to treat cancer.
CL2011001254A1 (en) Pharmaceutical combination comprising an antibody that specifically recognizes cd38 and at least melphalan; and its use for cancer treatment.
CL2009000545A1 (en) Use of a c-met antagonist and a her antagonist for the treatment of cancer.
CL2007000311A1 (en) Compounds derived from chromen-2-one; pharmaceutical composition that includes them; and their use in the treatment of a proliferative disorder such as cancer.
CL2011002877A1 (en) Antibody that recognizes the fnd1 domain of the ax1 receptor; pharmaceutical composition comprising it; and its use to treat cancer.
CL2011000191A1 (en) Compounds derived from substituted fused pyrimidine, mtor inhibitors; pharmaceutical composition that includes it; and use in the treatment of cancer.
CL2007001995A1 (en) Compounds derived from pyrrolotriazine; pharmaceutical composition comprising said compounds; and its use to treat cancer.
CL2012002189A1 (en) Compounds derived from substituted pyrrolidine-2-carboxamides; mdm2-p53 interaction inhibitors; pharmaceutical composition; and its use for the treatment of cancer, particularly solid tumors.
CL2012003415A1 (en) Compounds derived from 2-oxo-piperidine and 1,1-dioxide-thiazine, mdm2 inhibitors; pharmaceutical composition that includes them; and its use for the treatment of cancer.
CL2015002472A1 (en) As inhibitors of mutant idh-yl-oxazolidin-2-ones 3-pyrimidin-4.
CL2011000691A1 (en) Compounds derived from substituted nicotinamide; pharmaceutical composition that includes them; use for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
CL2011000454A1 (en) Compounds derived from picolinamide, pim kinase inhibitors, associated with tumorigenesis; pharmaceutical composition that includes them; and its use in the treatment of cancer.
CL2011000527A1 (en) Compounds derived from benzofuran; pharmaceutical composition that includes them; and their use in the treatment of hepatitis c.
CL2008001633A1 (en) Compounds derived from pyrrolidin-3-carboxamide; pharmaceutical composition; and use as erk inhibitors for the treatment of cancer.
CO6450665A2 (en) ANTI-FGFR3 ANTIBODIES AND METHODS THAT USE THEM
CL2007003226A1 (en) COMPOUNDS DERIVED FROM PIRIDINONA; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT CANCER.
GT200800202A (en) QUINAZOLINS FOR THE INHIBITION OF PDK1
CL2008002369A1 (en) Compounds derived from pyridin-3-yl-oxypyridin-2-yl-amino, alk5 inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cancer.
CL2007003212A1 (en) COMPOUNDS DERIVED FROM IMIDAZOPIRAZINS, INHIBITORS OF PROTEIN QUINASA; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM; AND ITS USE TO TREAT CANCER.
CL2008001323A1 (en) Triazolyl aminopyridine derived compounds; pharmaceutical composition comprising said compounds; and its use to treat cancer.
CL2010001538A1 (en) Compounds derived from substituted pyrazolo-quinazoline, modulators of the activity of protein kinases; pharmaceutical composition; and its use for the treatment of cancer, or a cell proliferative disorder.
CL2008000793A1 (en) COMPOUNDS DERIVED FROM DIHYDROINDAZOL; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT AN IRON DISORDER.
CL2008002430A1 (en) Benzenesulfonamide derived compounds, cathepsin c inhibitors; pharmaceutical composition comprising them; and its use for the treatment of copd.